Swiss drugmaker Roche’s logo is seen at their headquarters in Basel, Switzerland January 28, 2016. REUTERS/Arnd Wiegmann

ZURICH (Reuters) – Roche said on Thursday that the U.S. Food and Drug Administration had approved a treatment using its drugs Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukemia.

“Venclexta plus Gazyva is the only chemotherapy-free option of fixed duration that provides durable responses to help people live longer without progression of their disease, compared to a standard-of-care,” Roche’s Chief Medical Officer Sandra Horning said in a statement.

Reporting by Brenna Hughes Neghaiwi; Editing by Michelle Martin



READ SOURCE

READ  Boy, four, suffering from rare cancer pens heartbreaking letter to Father Christmas

WHAT YOUR THOUGHTS

Please enter your comment!
Please enter your name here